Alumis Phase 3 envudeucitinib hits PASI 90/100 endpoints in plaque psoriasis

ALUMIS INC.

PASI 90 at Week 24: 68.0% (ONWARD1) and 62.1% (ONWARD2); PASI 100: 41.0% and 39.5%.
Early onset: PASI 90 separation vs placebo by Week 4; itch relief by Week 2; scalp clearance in ~30% by Week 4.
Safety profile consistent with Phase 2; no new signals, mainly mild AEs (headache, nasopharyngitis, URTI, acne).
Company to submit NDA to FDA in H2 2026; Phase 3 long-term extension (ONWARD3) ongoing.
Also evaluating envudeucitinib in SLE LUMUS Phase 2b with topline data expected Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.